Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

NCT01053897 | Completed Phase 2 Results

• 1 other identifier: GBT-09-001
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 2

Brief Summary

The primary objective of this study is to assess whether intradermal injections of GBT009 along full thickness incisions following surgery results in an improvement in scar appearance.

Conditions

Scar Formation

Keywords

GBT009; incisional scar; breast reconstruction

Outcome Measures

Primary Outcomes (1)

• Photography- Independent Scar Assessment Panel

  An independent panel was planned to review scar photography to determine more preferable outcomes. Panel was not performed.

  0.5, 1, 2, 3, 6, 9 and 12 Months

Secondary Outcomes (3)

• Overall Scar Preference

  12 Month (End of Study)

• Patient Observer Scar Assessment Scale (POSAS)

  12 Month (End of Study)

• Manchester Scar Scale (MSS)

  12 Month (End of Study)

Study Arms (2)

GBT009

EXPERIMENTAL

Biological: GBT009

Placebo

PLACEBO COMPARATOR

Biological: Placebo

Interventions

GBT009 BIOLOGICAL

Intradermal Injection following surgery

GBT009

Placebo BIOLOGICAL

Intradermal Injection following surgery

Placebo

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• be a female between 18 and 70 years of age, inclusive
• have a body mass index ≤ 32 kg/m2 and a body weight between 50 and 95 kg, inclusive
• be scheduled for a mastectomy with breast reconstruction surgery using an abdominal flap technique
• for women diagnosed with breast cancer, has standard of care treatment for breast cancer prior to surgery and will have standard of care treatment for breast cancer after surgery
• for subjects of childbearing potential, be surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA through completion of the study and have negative results on a serum pregnancy test done before administration of study medication (women who are postmenopausal \[no menses for at least 2 years\] are also eligible to participate)
• be able to understand the study procedures, agree to participate in the study program, and voluntarily provide written informed consent

You may not qualify if:

• have clinically significant laboratory abnormalities at screening
• have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, coagulopathic disorder or other condition that would preclude participation in the study
• have received treatment for a severe, uncontrolled inflammatory disease or allergic condition within three months of screening
• have a life expectancy ≤ 2 years
• have a history of alcoholism or drug addiction or abuse within 5 years
• have evidence of a clinically significant abnormality upon evaluation of 12 lead ECG
• have evidence of any past or present clinically significant medical condition, including skin disease, that would impair wound healing
• have a history of keloid scar formation
• have existing scarring in the abdominal area of study that would interfere with the efficacy assessments
• have a history of (within the past 5 years) or an active malignancy, other than breast cancer
• have a breast cancer that has been staged at Stage IIIB, IIIC or IV
• have received a cytotoxic agent or have been treated with radiation within 90 days of screening and/or, in the opinion of the investigator, will likely require treatment in the 30 day period following the administration of study medication
• have received anticoagulation medication within 5 days of dosing with study medication
• have participated in any study involving an investigational product within 30 days before dosing with study medication
• have routinely used tobacco products within 6 months preceding the study period

Sponsors & Collaborators

• Garnet BioTherapeutics, Inc.: lead

Study Sites (2)

Garnet BioTherapeutics Investigational Site

Chicago, Illinois, United States

Location

Garnet BioTherapeutics Investigational Site

Rochester, New York, United States

Location

Limitations and Caveats

Study was discontinued early due to difficulty in identifying and enrolling eligible subjects.

Results Point of Contact

• Title: Gerri Henwood, CEO
• Organization: Garnet BioTherapeutics, Inc.

ghenwood@garnetbio.com

484-395-2440

Study Officials

• Garnet Study Manager

  Garnet BioTherapeutics, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 20, 2010
• First Posted: January 22, 2010
• Study Start: January 1, 2010
• Primary Completion: October 1, 2011
• Study Completion: October 1, 2011
• Last Updated: October 24, 2013
• Results First Posted: October 24, 2013

Record last verified: 2013-08

Locations

US (2)